1 Introduction: the pleiotropic revolution and the perioperative paradox The introduction of SGLT2 inhibitors—canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin—marked a watershed moment in metabolic medicine. By inhibiting the high-capacity, low-affinity glucose transporter in the S1 and S2 segments of the proximal renal tubule, these agents promote glycosuria, thereby lowering plasma glucose, weight, and blood pressure independent of insulin secretion (1).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Qingmin
Contact Qingmin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack